Canada & Dane Stevens

Canada: Canada's regulatory environment, where ibogaine is not a controlled substance and Optimi Health has GMP infrastructure and Canada — Health Canada licensing, positions it as an advantageous base for ibogaine manufacture and supply.

Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health, is leading the company's ibogaine initiative and highlights the growing interest and public funding for ibogaine research.

Canada: Canada is the country where Optimi Health manufactures its psilocybin and MDMA products at its GMP facility and from where it exports these products internationally.

Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health, expressed pride in the company's commercial supply of psilocybin and highlighted Australia's role as a model for regulated psychedelic medicine.

Canada: Canada is the location of Optimi Health's GMP facility where the psilocybin products are manufactured and from where Canada — Health Canada issues export authorizations.

Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health, highlighted the significance of the company's first shipment to the United Kingdom and its unique position as a vertically integrated GMP supplier.

Dane Stevens: Dane Stevens, CEO and Co-Founder of Optimi Health Corp., announced the launch of the new microdose psilocybin products, highlighting their consistent dosage for controlled research.